Shares of Evelo Biosciences Inc (NASDAQ:EVLO) have been given a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.
Analysts have set a 1-year consensus price objective of $26.67 for the company, according to Zacks. Zacks has also given Evelo Biosciences an industry rank of 103 out of 255 based on the ratings given to its competitors.
A number of brokerages have recently issued reports on EVLO. Cowen began coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating for the company. Morgan Stanley began coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “overweight” rating for the company. BMO Capital Markets assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, JMP Securities assumed coverage on Evelo Biosciences in a report on Monday, June 4th. They set an “outperform” rating and a $25.00 price target for the company.
Shares of EVLO stock traded down $0.82 during mid-day trading on Tuesday, reaching $12.67. The stock had a trading volume of 63,710 shares, compared to its average volume of 39,559. Evelo Biosciences has a one year low of $11.10 and a one year high of $16.75. The company has a current ratio of 24.08, a quick ratio of 24.08 and a debt-to-equity ratio of 0.09.
Evelo Biosciences (NASDAQ:EVLO) last issued its earnings results on Thursday, August 2nd. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.49). equities analysts anticipate that Evelo Biosciences will post -1.88 earnings per share for the current fiscal year.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.
See Also: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.